Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management
It is well known that hepatitis B virus reactivation (HBVr) can occur among patients undergoing treatment for hematological malignancies (HM). The evaluation of HBVr risk in patients undergoing immunosuppressive treatments is a multidimensional process, which includes conducting an accurate clinical...
Main Authors: | Alessandra Zannella, Massimo Marignani, Paola Begini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/11/9/858 |
Similar Items
-
Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment
by: Yu-Fen Tsai, et al.
Published: (2021-04-01) -
Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19
by: Caterina Sagnelli, et al.
Published: (2022-05-01) -
Regarding the problem of viral hepatitis reactivation in rheumatic diseases: risks and curation issues
by: B. S. Belov, et al.
Published: (2020-12-01) -
Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review
by: Zheng Yan, et al.
Published: (2023-08-01) -
Lower prevalence of hepatic fibrosis in low viremic hepatitis B patients with fluctuating HBV DNA levels
by: Faisal M Sanai, et al.
Published: (2022-01-01)